AZNAstraZenecaRunning, no new patients
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Non-Small Cell Lung Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due May 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 247 (final count)
- Started
- Jun 25, 2019
- Main results expected
- May 6, 2025
- Fully finished
- May 6, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR)
Measured over: Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-05-06, no fading
Raw record changes
- none yet
Trial ID NCT03944772 · record last updated 2025-01-30 · checked 2026-11-09 15:47 UTC